Coronary heart disease, stroke and coronary heart disease/heart failure patients. Number of cardiovascular events prevented by increasing uptake of aspirin, ACE inhibitors/A2 antagonists and influenza immunisation
| Condition (intervention) | Sex | Age group | Current treatment level | Incremental increase in treatment in those not contraindicated (peinc) | 5 year baseline risk of CVD event (P) | NEPP for CVD events |
|---|---|---|---|---|---|---|
| CHD = coronary heart disease; CVD = cardiovascular disease; ACE = angiotensin converting enzyme; A2 = angiotensin 2; NEPP = number of events prevented in population. | ||||||
| CHD (aspirin) | M | 45–64 | 81% | 9% | 12.8% | 0.25 |
| 65–84 | 81% | 9% | 30.0% | 0.49 | ||
| F | 45–64 | 80% | 10% | 6.6% | 0.07 | |
| 65–84 | 80% | 10% | 18.2% | 0.26 | ||
| Stroke (aspirin) | M | 45–64 | 81% | 9% | 17.0% | 0.07 |
| 65–84 | 81% | 9% | 40.0% | 0.21 | ||
| F | 45–64 | 80% | 10% | 8.8% | 0.03 | |
| 65–84 | 80% | 10% | 24.2% | 0.13 | ||
| CHD/HF (ACE inhibitors/A2 antagonists | M | 45–64 | 80% | 0% | 29.8% | 0.00 |
| 65–84 | 64% | 6% | 70% | 0.44 | ||
| F | 45–64 | 60% | 10% | 15.4% | 0.09 | |
| 65–84 | 52% | 18% | 42.4% | 0.66 | ||
| CHD (influenza immunisation) | M | 45–64 | 55% | 30% | 0.1% | 0.02 |
| 65–84 | 85% | 0% | 1.2% | 0.00 | ||
| F | 45–64 | 58% | 27% | 0.1% | 0.01 | |
| 65–84 | 84% | 1% | 1.2% | 0.00 | ||